07:14 AM EDT, 03/10/2025 (MT Newswires) -- Fennec Pharmaceuticals ( FENC ) , the developer of Pedmark, on Monday said its fourth-quarter net loss narrowed even as net sales fell.

The net loss narrowed to US$1.6 million, or US$0.06 per share, from US$2.7 million, or US$0.10 per share, in the previous corresponding quarter.

Net sales fell to US$7.9 million from US$9.7 million in the prior year period. For the full fiscal year 2024, sales increased 40% to US$29.6 million, due to strong growth in accounts and increased penetration in the adolescent and young market category, the company said.

Pedmark reduces the risk of hearing loss associated with cisplatin treatment in pediatric patients with certain types of tumors. In Japan, the clinical trial evaluating Pedmark fully enrolled in the fourth-quarter with results expected in the second half of this year.